Could it be Prof Jeffrey Lancet of Moffit CC, appointed to our SAB in 2015 who has or will be leaving PTX?
His work in oncology was described in the 2015 Dec Qtrly as "involved in the development and implementation of clincial trials using small molecule inhibitors in acute leukemias." So, given that PTX-200 has been morphed into CellPryme as a PH-domain inhibitor under our cell enhancement platform... and PTX-200 in its original form as a Targeted Therapy is nearing its clincal conclusion AML (with us anyway). On top of this, we are advertising for a Clinical Project Manager!
Safe to conclude that focus is now with OmniCAR, CellPryme and PTX-100.
Is it pretty standard that employee options expire upon leaving a company? If so, was it Prof JL who converted 50,000 oppies at a cost of about $18k as a thankyou to PTX and a show of confidence in our technologies?
Ann: Application for quotation of securities - PTX, page-7
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.002(4.76%) |
Mkt cap ! $32.21M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.1¢ | 4.0¢ | $27.92K | 697.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 638470 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 120000 | 2 |
View Market Depth
| Last trade - 11.27am 19/06/2024 (20 minute delay) ? |
| PTX (ASX) Chart |